SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 717.91 |
| Enterprise Value ($M) | 773.09 |
| Book Value ($M) | 290.71 |
| Book Value / Share | 2.15 |
| Price / Book | 2.47 |
| NCAV ($M) | -78.45 |
| NCAV / Share | -0.58 |
| Price / NCAV | -9.15 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.04 |
| Return on Assets (ROA) | -0.03 |
| Return on Equity (ROE) | -0.05 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.21 |
| Current Ratio | 1.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 158.55 |
| Assets | 527.72 |
| Liabilities | 237.01 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 763.86 |
| Operating Income | -23.18 |
| Net Income | -21.34 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -36.90 |
| Cash from Investing | -26.37 |
| Cash from Financing | -7.03 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Tco Group Holdings, L.p. | 83.38 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,329 | 27,933 | 8.34 | |
| 4,639 | 23,441 | 19.79 | |
| 2,312 | 43,756 | 5.28 | |
| 1,342 | 24,447 | 5.49 | |
| 1,515 | 17,267 | 8.77 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IMVT – Immunovant, Inc. | INBX – Inhibrx Biosciences, Inc. |
| INDV – Indivior PLC | INSM – Insmed Incorporated |
| INVA – Innoviva, Inc. |
Financial data and stock pages provided by
Fintel.io